Company: RCUS
Filing Date: 2025-02-18
Form Type: 424B5
Source: 0001193125-25-028669
Chunk: 9

Company: Arcus Biosciences, Inc.
Filing Date: 2025-02-18
Form: 424B5
Chunk 9
---
824 shares of common stock. |

| Use of proceeds | We estimate that the net proceeds to us from this offering, after deducting underwriting discounts and commissions and estimated offering expenses payable by us, will be approximately $141.6 million. |

| We currently intend to use the net proceeds from this offering to fund ongoing research and development activities, including the clinical development of casdatifan, manufacturing-related costs and other general 
 corporate purposes, including working capital and operating expenses. See “Use of Proceeds” on page S-11 of this prospectus supplement.                                                                             |

| New York Stock Exchange trading symbol | Our shares of common stock are listed on the New York Stock Exchange under the symbol “RCUS.” |

The number of shares of our common stock to be outstanding after this offering is based on 91,501,460 shares of our common stock outstanding as of September 30, 2024, and excludes:

| • |     | 15,464,177 shares of our common stock issuable upon the exercise of all stock options outstanding as of 
 September 30, 2024, at a weighted-average exercise price of $20.36 per share;                           |

| • |     | 3,044,956 shares of common stock issuable upon the exercise of stock options granted after September 30, 
 2024, with a weighted-average exercise price of $13.40 per share;                                        |

| • |     | 2,992,440 shares of our common stock issuable upon the vesting and settlement of all restricted stock units 
 outstanding as of September 30, 2024;                                                                       |

| • |     | 2,269,342 shares of common stock issuable upon the vesting and settlement of restricted stock units granted after 
 September 30, 2024;                                                                                               |

| • |     | up to an aggregate of 3,361,786 shares of common stock reserved for issuance pursuant to future awards under                                                                                                                          
 our 2018 Equity Incentive Plan (our “Equity Incentive Plan”), as of September 30, 2024, as well as any annual automatic increases in the number of shares of our common stock reserved for future issuance under the Equity Incentive 
 Plan;                                                                                                                                                                                                                                 |

| • |     | up to an aggregate of 2,694,420 shares of common stock reserved for issuance pursuant to future awards under our 
 2020 Inducement Plan (our “Inducement Plan